How long does tirzepatide stay in your system? A practical estimate is 25–30 days after the last dose. Tirzepatide's elimination half-life is about five to six days, so five half-lives leave roughly 3% of the starting amount. That does not mean its effects switch off on day 30. Levels fall continuously, and side effects, appetite, blood glucose, and weight changes do not all follow the same clock.
How long does tirzepatide stay in your system after the last dose?
Half-life is the time required for the amount of a drug in the body to fall by half. A population pharmacokinetic analysis pooling 19 tirzepatide studies found a half-life of about five days (Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024). The current U.S. prescribing information gives a range of approximately five to six days in people with overweight or obesity.
Using that range, the arithmetic looks like this:
| Half-lives after the last dose | Approximate time | Amount remaining |
|---|---|---|
| 1 | 5–6 days | 50% |
| 2 | 10–12 days | 25% |
| 3 | 15–18 days | 12.5% |
| 4 | 20–24 days | 6.25% |
| 5 | 25–30 days | 3.125% |
The estimate is therefore 5 half-lives × 5–6 days = 25–30 days. “Cleared” is shorthand here, not literal zero. A small amount remains after five half-lives, and metabolism varies between people. A laboratory detection window can also differ from the period in which the drug has a noticeable clinical effect.
The long tail comes from molecular design. Tirzepatide's fatty-acid side chain promotes strong binding to albumin, a protein circulating in blood, which slows clearance. The body then breaks the molecule down through peptide cleavage, fatty-acid oxidation, and amide hydrolysis. It is not stored unchanged for a month and then released all at once.
Peak level and steady state are different clocks
After an injection, the current label reports a median of about 24 hours to maximum concentration, with a range of 8–72 hours. Repeated weekly use builds exposure until the amount arriving and leaving becomes relatively balanced; the label places that steady state at about week 4. A phase 1 study also measured a roughly five-day half-life, consistent with weekly exposure (Furihata et al., Diabetes Obes Metab 2022).
This explains why “how long does tirzepatide take to work?” is not the inverse of clearance. Appetite or glucose effects may be noticed before week 4, while outcomes such as weight change are measured over much longer periods. Steady state means a stable exposure pattern, not the day a person should expect a particular result.
How long can side effects last after stopping?
There is no fixed side-effect washout day. Mild nausea, reduced appetite, constipation, or diarrhea associated with drug exposure may ease as the concentration declines over days to weeks. Their course depends on the symptom, the last dose, treatment duration, and whether a complication such as dehydration has developed.
The half-life is not a reason to wait out severe or persistent symptoms. Repeated vomiting or diarrhea, inability to keep fluids down, severe abdominal pain, or signs of an allergic reaction warrant prompt clinical assessment even though tirzepatide may remain in the body for weeks.
What the label says about a missed tirzepatide dose
The label uses a 96-hour decision point. It describes a missed dose as eligible to be given within four days; once more than four days have passed, that dose is skipped and the next dose falls on the regular scheduled day. The label also keeps at least 72 hours between two doses. These are descriptions of the labeled schedule, not personalized instructions; the prescriber sets the actual plan.
That four-day rule does not mean the previous dose has cleared. It is a scheduling rule built around sustained exposure. The dedicated tirzepatide dosage schedule explains how clinicians make broader titration decisions.
Clearance is not a switching schedule
A 25–30-day clearance estimate should not be converted into a self-directed gap before another GLP-1 medication. Semaglutide has its own longer half-life and exposure curve, covered in how long semaglutide stays in the system. Overlap, side effects, current dose, and the reason for treatment all matter. Switching from semaglutide to tirzepatide owns the clinical decision points; the reviewing prescriber chooses the timing.
Oral contraception and pregnancy use separate windows
Tirzepatide delays gastric emptying most after the first dose, then that effect diminishes. Because this can reduce absorption of oral hormonal contraception, the label describes a non-oral method or an added barrier method for four weeks after treatment starts and for four weeks after each dose increase. That four-week interval is about contraceptive absorption, not the time needed to eliminate tirzepatide. A published review found the tirzepatide interaction differed from the other GLP-1 medicines it assessed (Skelley et al., J Am Pharm Assoc 2024).
Pregnancy planning is another question. The current U.S. label says to discontinue when pregnancy is recognized and to tell the prescriber when pregnancy is planned, but it does not name a fixed preconception washout. European product information uses at least one month. A 2025 pharmacokinetic review proposed 25–35 days for tirzepatide before conception, while emphasizing that human pregnancy evidence remains limited (Alfaiz, Ann Med Surg 2025). The prescriber should set the individual timing, especially when stopping could affect glucose management.
Tirzepatide before surgery: guidance has changed
Tirzepatide can delay stomach emptying, which matters during general anesthesia or deep sedation. The label notes rare postmarketing reports of aspiration and says available data are insufficient to show whether temporarily stopping the medication reduces that risk. A one-week hold also is not a full washout: with a five-to-six-day half-life, roughly 38%–45% of the drug may still remain after seven days.
The 2023 anesthesia guidance suggested holding weekly GLP-1 medicines for seven days before an elective procedure. Multi-society guidance released in 2024 and published in 2025 moved to shared risk assessment rather than a universal hold (Kindel et al., Surg Endosc 2025). A 2025 SPAQI consensus likewise recommended continuation for patients without significant gastrointestinal symptoms, paired with a procedure-specific fasting plan (Oprea et al., Br J Anaesth 2025).
The practical answer is to make sure the surgical and anesthesia teams know about tirzepatide early. Whether to pause, continue, or restart around a procedure is a decision for the patient, prescriber, and anesthesia team.
Put the half-life into a clinical calendar
The 25–30-day estimate is useful for planning, but it is not a dosing, pregnancy, switching, or surgery protocol. The relevant date may be the last injection, a planned procedure, a dose increase, or an intended pregnancy, and each question uses the half-life differently.
At Promise, a licensed provider reviews every request and not everyone qualifies; when tirzepatide is prescribed, that provider determines the dose and timing plan from the person's history, medications, side effects, and goals.